Edgestream Partners L.P. Invests $2.38 Million in Charles River Laboratories International, Inc. (NYSE:CRL)

Edgestream Partners L.P. purchased a new position in Charles River Laboratories International, Inc. (NYSE:CRL) during the 4th quarter, Holdings Channel.com reports. The firm purchased 12,880 shares of the medical research company’s stock, valued at approximately $2,378,000.

Other large investors also recently bought and sold shares of the company. Versant Capital Management Inc increased its position in Charles River Laboratories International by 1,071.4% in the fourth quarter. Versant Capital Management Inc now owns 164 shares of the medical research company’s stock worth $30,000 after purchasing an additional 150 shares during the last quarter. Pinnacle Bancorp Inc. increased its position in Charles River Laboratories International by 52.0% in the fourth quarter. Pinnacle Bancorp Inc. now owns 190 shares of the medical research company’s stock worth $35,000 after purchasing an additional 65 shares during the last quarter. Assetmark Inc. increased its position in Charles River Laboratories International by 1,153.3% in the third quarter. Assetmark Inc. now owns 188 shares of the medical research company’s stock worth $37,000 after purchasing an additional 173 shares during the last quarter. ORG Wealth Partners LLC bought a new stake in Charles River Laboratories International in the fourth quarter worth $56,000. Finally, Wilmington Savings Fund Society FSB bought a new stake in Charles River Laboratories International in the third quarter worth $59,000. Institutional investors own 98.91% of the company’s stock.

Analysts Set New Price Targets

Several brokerages recently weighed in on CRL. TD Cowen boosted their price target on shares of Charles River Laboratories International from $203.00 to $227.00 and gave the stock a “hold” rating in a research report on Monday, November 11th. Bank of America lowered their target price on shares of Charles River Laboratories International from $220.00 to $210.00 and set a “neutral” rating for the company in a report on Friday, December 13th. Citigroup upgraded shares of Charles River Laboratories International from a “sell” rating to a “neutral” rating and upped their price target for the company from $155.00 to $175.00 in a report on Tuesday, March 4th. Morgan Stanley decreased their price objective on shares of Charles River Laboratories International from $220.00 to $184.00 and set an “equal weight” rating for the company in a research note on Wednesday, February 5th. Finally, William Blair cut Charles River Laboratories International from an “outperform” rating to a “market perform” rating in a research note on Wednesday, January 22nd. One research analyst has rated the stock with a sell rating, fifteen have assigned a hold rating and one has given a buy rating to the company’s stock. According to MarketBeat.com, the stock currently has an average rating of “Hold” and a consensus price target of $198.36.

Charles River Laboratories International Price Performance

Shares of CRL stock opened at $176.20 on Monday. Charles River Laboratories International, Inc. has a twelve month low of $150.79 and a twelve month high of $274.77. The stock has a market capitalization of $9.01 billion, a price-to-earnings ratio of 1,174.68, a P/E/G ratio of 4.54 and a beta of 1.45. The stock has a fifty day simple moving average of $169.15 and a two-hundred day simple moving average of $185.63. The company has a current ratio of 1.41, a quick ratio of 1.14 and a debt-to-equity ratio of 0.65.

Charles River Laboratories International (NYSE:CRL) last issued its earnings results on Wednesday, February 19th. The medical research company reported $2.66 earnings per share for the quarter, topping the consensus estimate of $2.50 by $0.16. Charles River Laboratories International had a return on equity of 14.69% and a net margin of 0.52%. The business had revenue of $1 billion during the quarter, compared to analysts’ expectations of $983.63 million. During the same period in the prior year, the business earned $2.46 EPS. The business’s revenue for the quarter was down 1.1% compared to the same quarter last year. On average, analysts predict that Charles River Laboratories International, Inc. will post 9.36 EPS for the current fiscal year.

Insiders Place Their Bets

In related news, COO Birgit Girshick purchased 1,514 shares of Charles River Laboratories International stock in a transaction dated Thursday, February 20th. The stock was purchased at an average cost of $164.63 per share, with a total value of $249,249.82. Following the transaction, the chief operating officer now owns 55,058 shares in the company, valued at approximately $9,064,198.54. The trade was a 2.83 % increase in their position. The purchase was disclosed in a document filed with the Securities & Exchange Commission, which can be accessed through this hyperlink. Also, CEO James C. Foster purchased 6,075 shares of Charles River Laboratories International stock in a transaction dated Thursday, February 20th. The stock was bought at an average cost of $165.01 per share, with a total value of $1,002,435.75. Following the completion of the transaction, the chief executive officer now owns 183,639 shares in the company, valued at approximately $30,302,271.39. This represents a 3.42 % increase in their position. The disclosure for this purchase can be found here. Company insiders own 1.30% of the company’s stock.

About Charles River Laboratories International

Charles River Laboratories International, Inc provides drug discovery, non-clinical development, and safety testing services in the United States, Europe, Canada, the Asia Pacific, and internationally. It operates through three segments: Research Models and Services (RMS), Discovery and Safety Assessment (DSA), and Manufacturing Solutions (Manufacturing).